Related references
Note: Only part of the references are listed.Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model
Pasi Vottonen et al.
ACTA OPHTHALMOLOGICA (2016)
SOCIETAL COSTS ASSOCIATED WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION IN THE UNITED STATES
Melissa M. Brown et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2016)
A randomised controlled trial to assess the clinical effectiveness and cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)
Usha Chakravarthy et al.
HEALTH TECHNOLOGY ASSESSMENT (2015)
Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold
Karl Claxton et al.
HEALTH TECHNOLOGY ASSESSMENT (2015)
BANNER Why have UK doctors been deterred from prescribing Avastin?
Deborah Cohen
BMJ-BRITISH MEDICAL JOURNAL (2015)
BANNER Why have UK doctors been deterred from prescribing Avastin?
Deborah Cohen
BMJ-BRITISH MEDICAL JOURNAL (2015)
A prospective, observational, open-label, multicentre study to investigate the daily treatment practice of ranibizumab in patients with neovascular age-related macular degeneration
Freekje van Asten et al.
ACTA OPHTHALMOLOGICA (2015)
Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis
Martin K. Schmid et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration
Frank G. Holz et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2015)
CAUSES FOR CONCERN: IS NICE FAILING TO UPHOLD ITS RESPONSIBILITIES TO ALL NHS PATIENTS?
Karl Claxton et al.
HEALTH ECONOMICS (2015)
The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters
Mari Elshout et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2014)
Cost-Effectiveness of Bevacizumab and Ranibizumab for Newly Diagnosed Neovascular Macular Degeneration
Joshua D. Stein et al.
OPHTHALMOLOGY (2014)
Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial
Helen A. Dakin et al.
BMJ OPEN (2014)
Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis
Wan Ling Wong et al.
LANCET GLOBAL HEALTH (2014)
Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - A noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany
Robert P. Finger et al.
ACTA OPHTHALMOLOGICA (2013)
Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK
Tiarnan D. L. Keenan et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2013)
A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration
Ilse Krebs et al.
BRITISH JOURNAL OF OPHTHALMOLOGY (2013)
Twelve-Month Efficacy and Safety of 0.5 mg or 2.0 mg Ranibizumab in Patients with Subfoveal Neovascular Age-related Macular Degeneration
Brandon G. Busbee et al.
OPHTHALMOLOGY (2013)
Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial
Laurent Kodjikian et al.
OPHTHALMOLOGY (2013)
CHANGES IN VISUAL ACUITY IN PATIENTS WITH WET AGE-RELATED MACULAR DEGENERATION TREATED WITH INTRAVITREAL RANIBIZUMAB IN DAILY CLINICAL PRACTICE The LUMIERE Study
Salomon Y. Cohen et al.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES (2013)
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
Don Husereau et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD
Konrad R. Koch et al.
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY (2012)
Can next-generation antibodies offset biosimilar competition?
Asher Mullard
NATURE REVIEWS DRUG DISCOVERY (2012)
Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular Degeneration
Jeffrey S. Heier et al.
OPHTHALMOLOGY (2012)
Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6
Andrew H. Briggs et al.
VALUE IN HEALTH (2012)
Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration The CATT Research Group
Daniel F. Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Bevacizumab vs ranibizumab for age-related macular degeneration: 1-year outcomes of a prospective, double-masked randomised clinical trial
M. L. Subramanian et al.
EYE (2010)
Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye Clinical Trial Results from MARINA and ANCHOR
Neil M. Bressler et al.
OPHTHALMOLOGY (2010)
A Phase IIIb Study to Evaluate the Safety of Ranibizumab in Subjects with Neovascular Age-related Macular Degeneration
David S. Boyer et al.
OPHTHALMOLOGY (2009)
A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration
Melissa M. Brown et al.
OPHTHALMOLOGY (2008)
Ranibizumab for neovascular age-related macular degeneration
Philip J. Rosenfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Ranibizumab versus verteporfin for neovascular age-related macular degeneration
David M. Brown et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
